성견의 외과적 치근이개부 골결손에 차폐막과 골이식재를 이용한 조직유도재생술시 치유양상

정은희,정현주,Chung, Eun-Hee,Chung, Hyun-Ju 대한치주과학회 1996 Journal of Periodontal & Implant Science Vol.26 No.4

The present study was to evaluate the healing patterns of guided tissue regeneration( GTR) using resorbable $Vicryl^{(R)}$(polyglactin 910) mesh and nonresorbable expanded polytetrafluoroethylene(ePTFE) membrane with or without bone grafting using autogeneous bone and demineralized freeze-dried bone allograft(DFDBA) in the grade II furcation defects. Mucoperiosteal flaps were reflected buccally in the mandibular 2nd, 3rd and 4th premolar areas and furcation defects were created surgically by removing $5{\times}6mm$ alveolar bone in 4 dogs. Root surfaces were thoroughly debrided of periodontal ligament and cementum, and notches were placed on root surface at the most apical bone level. In the right and left mandibular quadrant, each tooth was received $Vicryl^{(R)}$ mesh(ACE Surgical Supply Co., USA) only, $Vicryl^{(R)}$ mesh with DFDBA, $Vicryl^{(R)}$ mesh with autogeneous bone grafts, ePTFE membrane($Core-tex^{(R)}$ membrane, W.L. Gore & Associates Inc., USA) only, ePTFE membrane with DFDBA or ePTFE membrane with autogeneous bone grafts. For the fluorescent microscopic examination, fluorescent agents were injected at 2, 4 and 8 weeks after surgery. Four weeks after surgery, 2 dogs were sacrificed and ePTFE membranes were removed from remaining 2 dogs, which were sacrificed at 12 weeks after surgery. Undecalcified tissues were embedded in methylmethacrylate and $10{\mu}m$ thick sections were cut in a buccolingual direction. These sections were stained with hematoxylin-eosin stain and Masson's trichrome stain, and evaluated by descriptive histology and linear measurements. The results were as follows : 1) $Vicryl^{(R)}$ mesh group showed less connective tissue attachment than ePTFE membrane group. 2) The combination of GTR using $Vicryl^{(R)}$ mesh and osseous grafts resulted in new attachment and new bone formation more than GTR using $Vicryl^{(R)}$ mesh only. 3) GTR using ePTFE membrane, with or without osseous grafts, enhanced periodontal regeneration. 4) Root resorption and dentoalveolar ankylosis were observed in the areas treated with the combination of GTR and DFDBA. It was suggested that the effect of adjunctive bone grafting in GTR procedure depends on the materials and the physical properties of barrier membranes. $Vicryl^{(R)}$ mesh performed a barrier function and the use of adjunctive bone grafting may enhance the periodontal regeneration.

사파이어 기판에 펄스 레이저 증착법으로 성장된 AlN 박막의 특성

정은희,정준기,정래영,김성진,박상엽,Jeong, Eun-Hee,Chung, Jun-Ki,Jung, Rae-Young,Kim, Sung-Jin,Park, Sang-Yeup 한국세라믹학회 2013 한국세라믹학회지 Vol.50 No.6

AlN films with c-axis orientation and thermal conductivity characteristics were deposited by using Pulsed Laser Deposition and the films were characterized by changing the deposition conditions. In particular, we investigated the optimal conditions for the application of a heat sinking plane AlN thin film. Epitaxial AlN films were deposited on sapphire ($c-Al_2O_3$) single crystals by pulsed laser deposition (PLD) with an AlN target. AlN films were deposited at a fixed pressure of $2{\times}10^{-5}$ Torr, while the substrate temperature was varied from 500 to $700^{\circ}C$. According to the experimental results of the growth temperature of the thin film, AlN thin films were confirmed with a highly c-axis orientation, maximum grain size, and high thermal conductivity at $650^{\circ}C$. The thermal conductivity of the AlN thin film was found to increase compared to bulk AlN near the band gap value of 6.2 eV.

치근면에 도포된 Tetracycline의 유리양상에 관한 연구

정은희,정현주,Jeong, Eun-Hee,Chung, Hyun-Ju 대한치주과학회 1989 Journal of Periodontal & Implant Science Vol.19 No.2

일차성 면역결핍질환에서의 예후인자: 감염과 호흡기 합병증

정은희 ( Eun Hee Chung ) 대한소아알레르기 및 호흡기학회 2007 소아알레르기 및 호흡기학회지 Vol.17 No.4

한국 영아에서 B형 간염과 PRP-OMP의 혼합백신(Comvax™; MSD사)의 면역원성 및 안전성

정은희 ( Eun Hee Chung ),마상혁 ( Sang Hyuck Ma ),홍영진 ( Young Jin Hong ),김경효 ( Kyung Hyo Kim ),김종현 ( Jong Hyun Kim ),이진아 ( Jin A Lee ),이환종 ( Hoan Jong Lee ) 대한소아감염학회 2006 Pediatric Infection and Vaccine Vol.13 No.2

목 적 : 근래에 영아 백신의 숫자가 증가하면서 동시에 접종하는 혼합백신의 개발이 증가하고 있다. 본 연구에서는 우리나라 영아에서 b형 H. influenzae에 대한 단백 결합 백신(PRP-OMP)과 B형 간염 백신의 혼합백신인 Comvax™(Merck & Co.)의 면역원성 및 안전성을 평가하고자 하였다. 대상 및 방법 : 생후 직후 B형 간염 백신(유박스 B™ 또는 헤파박스-진™)을 접종받은 영아를 대상으로 Comvax™를 단독으로 또는 DTaP, IPV, Prevenar 등과 2, 4개월에 접종한 후, 2회 접종 전(4개월 연령) 및 2회 접종 2개월 후(6개월 연령)에 혈청 내 항 PRP 항체가와 anti-HBs를 효소면역법과 chemiluminescent microparticle immunoassay로 측정하였다. 결 과 : 총 65명(남아 35명)이 포함되었으며, 58명이 계획된 접종을 완료하였다. 1회 접종 후 항PRP 항체가의 기하 평균치는 1.96 ㎍/mL(95% CI 1.38~2.78), 2회 접종 후의 기하평균치는 10.02 ㎍/mL(95% CI 7.04~14.26)이었다. 항체가가 1.0 ㎍/mL 이상인 비율은 1회 접종 후 63.2%(95% CI 53.75~72.65), 2회 접종 후 96.6%(95% CI 93.05~100)이었다. 한편 anti-HBs가 10 mIU/mL 이상인 영아의 비율은 4개월에 73.7%(95% CI 65.07~82.33), 6개월에 94.8%(95% CI 90.45~99.15)이었으며, 기하 평균치는 4개월에 38.32 mIU/mL(95% CI 22.42~65.51), 6개월에 101.17 mIU/mL(95% CI; 65.94~155.25)이었다. 백신 접종 후 발생한 이상반응 중 전신 증세로서 보챔(24.8%)이 가장 많았고 졸음(19.2%), 식욕부진(19.2%) 그리고 발열(7.2%) 등이 있었다. 국소 증세로는 동통이 25.6%, 발적이 19.2%, 부종이 4.8%에서 관찰되었다. 이러한 이상반응은 대부분 경증에 속하는 것으로 모두 회복되었다. 결 론 : Comvax™는 우리나라 영아에서 안전하고, 매우 우수한 항-PRP 항체 반응을 보였으며, 본 연구에서 B형 간염에 대해서는 아직 표준화되지 않은 방법으로 접종되었으나 비교적 우수한 항체 반응을 보여 B형 간염에 대해서도 우수한 면역원성을 지녔을 것으로 추측된다. Purpose : To reduce the number of injections necessary to vaccinate young infants, various combined vaccines have been developed. The Comvax™ manufactured by Merck & Co. is a combination of Hepatitis B and PRP-OMP conjugate Haemophilus influenzae Type b vaccine. The purpose of this study is to evaluate the immunogenicity and safety of Comvax™ in Korean infants. Methods : The infants who were vaccinated at 0 months of age with Hepatitis B vaccine, were recruited for this study after parental informed consent was obtained. The subjects were vaccinated with Comvax™ at 2 and 4 months of age. At each visit, infants were also immunized with DTaP, inactivated poliovirus vaccine, and pneumococcal vaccine when indicated. The serum anti-PRP and anti-HBs were measured at 2 months after the 1st dose(4 months age), and the 2nd dose(6 months age) by the ELISA and chemiluminescent microparticle immunoassay method, respectively. The local and systemic adverse reactions of vaccination were monitored for 3 consecutive days after each immunization. Results : Among sixty-five healthy infants(35 male infants) enrolled in this study; fifty eight(32 male infants) completed the scheduled immunizations. The geometric mean titers (GMTs) of anti-PRP at 2 months after the 1st dose and the 2nd dose were 1.96 μg/mL (95% CI; 1.38∼2.78) and 10.02 μg/mL (95% CI; 7.04∼14.26), respectively. Anti-PRP ≥1.0 μg/mL, was obtained in 63.2%(95% CI; 53.75∼72.65) after 1 dose, and 96.6%(95% CI; 93.05∼100) after 2 doses. The GMTs of anti-HBs were 38.32 mIU/mL(95% CI; 22.42∼ 65.51), and 101.17 mIU/mL(95% CI; 65.94∼155.25) at 2 month after the 1st dose and 2nd dose of Comvax™, respectively. Anti-HBs ≥10 mIU/mL was observed in 73.7%(95% CI; 65.07∼82.33) after 1 dose and 94.8%(95% CI; 90.45∼99.15) after 2 doses. Most of the adverse reactions after vaccination were mild. Irritability, the most common systemic reaction, was observed in 24.8%, followed by drowsiness(19.2%), poor feeding(19.2%) and fever(7.2%). Among the local reactions tenderness was observed in 25.6%, redness(≥ 5 mm) in 19.2% and swelling(≥5 mm) in 4.8%. Conclusion : The Comvax™ vaccine was highly immunogenic for PRP and safe in Korean infants. Although the hepatitis B vaccine component was administered at 0, 2, 4 months, this study showed good immunogenicity against HBsAg.

소아에서의 약물유해반응 감시의 임상적 의의

정은희 ( Eun Hee Chung ) 대한천식알레르기학회(구 대한알레르기학회) 2016 Allergy Asthma & Respiratory Disease Vol.4 No.5

코로나바이러스감염증-19 (coronavirus disease 2019) 백신과 이상 반응

정은희 ( Eun Hee Chung ) 대한천식알레르기학회(구 대한알레르기학회) 2021 Allergy Asthma & Respiratory Disease Vol.9 No.3

In order to overcome the global pandemic of the new pathogen, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), intensive research has been conducted to understand viral pathogenicity, establish effective treatment strategies, and develop vaccines against coronavirus disease 2019 (COVID-19). To prevent COVID-19, a variety of COVID-19 vaccines have been rapidly developed and are currently being administered worldwide. When developing new vaccines, monitoring for adverse events following immunization (AEFIs) has always been important, and some COVID-19 vaccines are particularly effective as new types of vaccines that have not been used before, thus attracting attention to AEFIs. Vaccine administration is carefully conducted while monitoring for AEFI that are being reported from time to time. AEFIs are largely divided into local reactions, systemic reactions, allergic reactions, and adverse reactions to specific diseases or disease- attributable events. In addition, it is classified according to causes, but it is very difficult to confirm the association with the vaccine. Anaphylaxis, which is a systemic reaction among serious allergic reactions, requires immediate treatment and may require testing to determine the cause. In order to increase the vaccination rate and secure herd immunity, there should be no fear of vaccination due to unidentified side effects. Therefore, monitoring of AEFIs is important and causal relationships must be well established based on reliable epidemiological investigations. Current data show that the benefits of a COVID-19 vaccine far outweigh the risk of AEFIs. Future studies should continue to understand the mechanisms and risk factors of identified adverse reactions. (Allergy Asthma Respir Dis 2021;9:124-135)

흡입화상에 의한 반응성 기도과민 증후군

정은희 ( Eun Hee Chung ),장영표 ( Young Pyo Chang ),박우성 ( Woo Sung Park ),지영구 ( Young Koo Jee ),이영석 ( Young Suk Lee ),이인선 ( In Sun Lee ),신미용 ( Mee Yong Shin ) 대한소아알레르기호흡기학회(구 대한소아알레르기 및 호흡기학회) 2005 소아알레르기 및 호흡기학회지 Vol.15 No.3

우리나라 영아에서 PRP-T(Hiberix™)백신의 면역원성 및 안전성에 대한 연구

정은희 ( Eun Hee Chung ),김예진 ( Yae Jean Kim ),김윤경 ( Yun Kyung Kim ),김동호 ( Dong Ho Kim ),서정완 ( Jeong Wan Seo ),이환종 ( Hoan Jong Lee ) 대한소아감염학회 2003 Pediatric Infection and Vaccine Vol.10 No.1

목 적 : b형 Haemophilus influenzae(Hib)의 피막 다당질인 polyribosyl -ribitol-phosphate(PRP)가 Hib 질환의 발병기전에 중요한 역할을 하며, 이에 대한 항체가 있으면 Hib 질환을 예방할 수 있다. Hib 질환을 예방하기 위해 개발된 단백 결합 백신에는 PRP-D, PRP-T, PRP-OMP 및 PRP-CRM197 등이 있다. Hib 피막 다당질에 대한 항체 반응은 백신에 사용된 결합 단백의 종류에 따라 다르지만 인종이나 제조 회사에 따라서 유효성 및 안전성에 차이가 있을 수 있다. PRP-T에는 기존에 국내에 공급되던 ActHib®(Aventis)와 최근에 국내에 도입되기 시작한 Hiberix™(GlaxoSmithKline Biologicals)가 있다. 본 연구에서는 우리나라 영아에서 PRP-T 백신인 Hiberix™의 면역원성 및 안전성을 평가하고자 하였다. 방 법 : 2001년 3월부터 2002년 4월까지 소아과에 예방접종을 위해 내원한 건강한 생후 2개월 이상의 영아 73명(남아 43명)을 대상으로 하였다. 생후 2, 4, 6개월에 PRP-T 백신(Hiberix™)을 필요한 경우에 DTaP, TOPV, B형 간염백신과 같이 접종하였고, 1회 접종 전(2개월), 2회 접종 2개월 후(생후 6개월) 그리고 3회 접종 1개월 후(생후 7개월)에 혈청내 항 PRP 항체가를 효소면역법(ELISA)으로 측정하였다. 매 접종 후 72시간내에 발생하는 국소적, 전신적 이상반응을 관찰하였다. 면역원성은 계획한대로 접종을 완료한 영아에 대하여 분석하였으며, 이상반응은 1회 이상 접종받은 모든 영아에 대하여 분석하였다. 결 과 : 73명 중 63명(남아 37명)이 계획한대로 접종을 완료하였다. 생후 2개월에 측정한 접종 전항 PRP 항체가의 기하 평균치는 0.17 ㎍/mL(95% CI; 0.13~0.22)이었다. 2회 접종 후(생후 6개월) 항체가의 기하 평균치는 4.14 ㎍/mL(95% CI; 2.65~6.48), 3회 접종 후(생후 7개월)의 기하 평균치는 14.65 ㎍/mL(95% CI; 10.83~19.81)이었다. 항체가가 1.0 ㎍/mL 이상인 비율은 2회 접종 후 77.8% (95% CI; 67.5~88.0), 3회 접종 후 98.4%(95% CI;95.3~100)이었다. 백신 접종 후 발생한 이상반응중 전신반응으로서 보챔(45.5%)이 가장 많았고 졸음(30.5%), 수유감소(26.7%), 발열(5.6%) 순이었다. 국소반응으로서 동통이 7.9%, 발적(≥5 mm) 2.8%, 부종(≥5 mm) 1.8% 순이었다. 이러한 이상반응은 대부분 경증으로 모두 회복되었다. 결 론 : 결론적으로, PRP-T 백신인 Hiberix™는 우리나라 영아에서 우수한 면역원성과 안전성을 보였으며, 특히 2회 접종으로도 항체가의 기하 평균치가 장기적인 방어 수준으로 상승함은 과거의 다른 PRP-T 백신(ActHib®)의 연구 결과들과 일치하는 소견으로 향후 국내에서 PRP-T 백신의 접종 방법에 대한 재고가 필요하다고 사료된다. Purpose : Four kinds of Haemophilus influenzae type b protein conjugate vaccines, PRPD, PRP-T, PRP-OMP and PRP-CRM197, have been developed, and PRP-T vaccines are currently produced by two manufacturer, ActHib® by Aventis and Hiberix™ by GlaxoSmith- Kline Biologicals. The purpose of this study is to evaluate the immunogenicity and safety of Hiberix™ in Korean infants. Methods : Seventy-three healthy infants(43 male infants) were recruited for this study after parental informed consent was obtained. Each infant was vaccinated at 2, 4 and 6 months of age with the study vaccine. At each visit, infants were also immunized with DTaP, trivalent oral polio vaccine and hepatitis B vaccine when indicated. The serum anti- PRP antibody was measured at prevaccination, 2 month later after the 2nd dose, and 1 month later after the 3rd dose by the ELISA method. The local and systemic adverse reactions of vaccination were monitored for 3 consecutive days after each immunization. Immunogenicity of vaccine was evaluated in infants who received all the scheduled immunization and the adverse reactions were evaluated for infants who received at least one dose of the study vaccine. Results : Among seventy three infants, enrolled in this study; sixty three(37 male infants) completed all the scheduled immunizations. The geometric mean titer(GMT) of anti-PRP antibodies at prevaccination was 0.17 μg/mL(95% confidence interval[CI]; 0.13~0.22). The GMT of anti-PRP antibodies increased to 4.14 μg/mL(95% CI; 2.65~6.48) at 2 month later after the 2nd dose of PRP-T and 14.65 μg/mL(95% CI; 10.83∼19.81) at 1 month later after the 3rd dose. Anti-PRP antibody ≥0.15 μg/mL, was observed in 98.4%(95% CI; 91.8~100) after 2 doses and 100%(95% CI; 100~100) after 3 doses. Anti-PRP antibody ≥1.0 μg/mL, was obtained in 77.8%(95% CI; 67.5~88.0) after 2 doses, and 98.4%(95% CI; 95.3~100) after 3 doses. Most of the adverse reaction after vaccination were mild. Irritability, the most common systemic reaction, was observed in 45.5%, followed by drowsiness(30.5%), poor feeding(26.7%) and fever(5.6%). Among the local reactions tenderness was observed in 7.9%, redness(≥5 mm) in 2.8% and swelling(≥5 mm) in 1.8%. Conclusion : The PRP-T vaccine used in this study was highly immunogenic and safe in Korean young infants. The finding that high GMT and high frequency of infants with a protective titer achieved after 2 doses is consistent with the previous studies which were done with a PRP-T vaccine of other manufacturer. This study suggests that the immunization schedule of PRP-T vaccine for Korean infants may need re-evaluation.

AI 디자인 툴의 디자인 업무 지원 방향성 제안

정은희(Eun Hee Chung),최정민(Jung Min Choi) 한국디자인학회 2022 디자인학연구 Vol.35 No.4